---
title: "Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-Q: FY2025 Q2 Revenue: USD 797.4 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257215449.md"
published_at: "2025-09-13T21:14:36.000Z"
---

# Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-Q: FY2025 Q2 Revenue: USD 797.4 M

Revenue: As of FY2025 Q2, the actual value is USD 797.4 M.

EPS: As of FY2025 Q2, the actual value is USD 0.05.

EBIT: As of FY2025 Q2, the actual value is USD 11.9 M.

### BSI BioSpin

-   **Revenue**: $195.3 million, a decrease of 10.2% from $217.5 million in Q2 2024.
-   **Gross Profit**: $87.2 million, a decrease from $106.7 million in Q2 2024.
-   **Gross Margin**: 44.6%, down from 49.1% in Q2 2024.

### BSI CALID

-   **Revenue**: $285.8 million, an increase of 7.6% from $265.6 million in Q2 2024.
-   **Gross Profit**: $137.2 million, an increase from $128.1 million in Q2 2024.
-   **Gross Margin**: 48.0%, slightly down from 48.2% in Q2 2024.

### BSI NANO

-   **Revenue**: $252.1 million, a slight decrease of 0.2% from $252.5 million in Q2 2024.
-   **Gross Profit**: $112.1 million, a decrease from $115.7 million in Q2 2024.
-   **Gross Margin**: 44.5%, down from 45.8% in Q2 2024.

### BEST

-   **Revenue**: $66.3 million, a decrease of 4.1% from $69.1 million in Q2 2024.
-   **Gross Profit**: $21.4 million, a decrease from $23.1 million in Q2 2024.
-   **Gross Margin**: 32.3%, down from 33.4% in Q2 2024.

### Consolidated Results

-   **Total Revenue**: $797.4 million, a decrease of 0.4% from $800.7 million in Q2 2024.
-   **Total Gross Profit**: $357.9 million, a decrease from $384.6 million in Q2 2024.
-   **Total Gross Margin**: 44.9%, down from 48.0% in Q2 2024.

### Operating Expenses

-   **Selling, General and Administrative**: $231.4 million, an increase of 4.6% from $221.3 million in Q2 2024.
-   **Research and Development**: $100.2 million, an increase of 8.7% from $92.2 million in Q2 2024.
-   **Other Charges, Net**: $14.4 million, a decrease from $23.0 million in Q2 2024.

### Operating Income

-   **Operating Income**: $11.9 million, a decrease of 75.3% from $48.1 million in Q2 2024.
-   **Operating Margin**: 1.5%, down from 6.0% in Q2 2024.

### Net Income

-   **Net Income**: $7.6 million, unchanged from Q2 2024.

### Cash Flow

-   **Net Cash Provided by (Used in) Operating Activities**: - $127.5 million, a decrease from $1.1 million in Q2 2024.
-   **Free Cash Flow**: - $148.8 million, a decrease from - $23.5 million in Q2 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue focusing on its core business areas, with structured strategic plans tied to measurable goals such as growth targets, margin improvement, and market expansion.
-   **Non-Core Business**: The company is also exploring emerging segments and divestitures, with a focus on clarity and actionability.
-   **Priority**: Emphasis is placed on strategies with concrete projections or quantitative indicators over generic or vague statements.

### Related Stocks

- [BRKRP.US - Bruker Corp Pref Shares BRKRP 6.375 09/01/2028](https://longbridge.com/en/quote/BRKRP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 康寧｜10-K：2025 財年營收 156 億美元 |  | [Link](https://longbridge.com/en/news/275812620.md) |
| Trio-Tech 國際｜8-K：2026 財年 Q2 營收 15.65 百萬美元 |  | [Link](https://longbridge.com/en/news/275917124.md) |
| 易昆尼克斯｜10-K：2025 財年營收 92.17 億美元 |  | [Link](https://longbridge.com/en/news/275659807.md) |
| Baxter｜8-K：2025 財年 Q4 營收 29.74 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275754681.md) |
| Draftkings｜10-K：2025 財年營收 60.55 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275897859.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.